Bausch Health's brain dysfunction treatment fails late-stage trial
23/01/2026 12:50
Jan 23 (Reuters) - Bausch Health BHC.TO said on Friday its treatment to prevent brain dysfunction in patients with liver cirrhosis did not meet the main goal of a late-stage trial. (Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar) ((Christy.Santhosh@thomsonreuters.com;))
Recent news on Bausch Health Companies
See all newsBausch + Lomb CEO Saunders departs, Chairman Appio named interim chief (updated)
Brief: Bausch + Lomb And Bausch Health Announce Appointment Of Thomas J. Appio As Interim Bausch + Lomb CEO, Expect To Raise Full-Year 2026 Guidance
Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief
Brief: Bausch Health Companies -Co And Yun Expand Strategic Collaboration In Mexico And EMEA Markets
Canada Stocks: Toronto stocks near record high as investors weigh earnings, US PPI data